Compare Bristol-Myers Squibb Co (BMY) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Comcast Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.41 (market cap $116.30B), while Comcast Corporation trades at $23.66 (market cap $82.84B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Comcast Corporation pays the higher dividend (5.69%). Which is the better fit depends on your goals.
| BMY | CMCSA | |
|---|---|---|
Market Cap | $116.30B | $82.84B |
Sector | Health | Media |
52-Week High | $62.37 | $33.81 |
52-Week Low | $42.60 | $22.32 |
Enterprise Value | $152.24B | $167.98B |
Dividend Yield | 4.42% | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Comcast (CMCSA) trades at $23.97, up 1.7% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 16.16% net margin and attractive valuation metrics including P/E of 4.7 and P/B of 0.97. Recent quarterly earnings consistently beat expectations, while strategic moves include the NBCUniversal spin-off and Sky's acquisition of ITV's media unit for $2.14 billion.
The stock presents compelling value with significant upside to the $29.94 consensus target. However, investors face risks from Starlink competition and integration challenges from recent acquisitions. Wall Street maintains strong buy sentiment with 58% analyst support, but execution risks and sector disruption threats warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
